Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam in Subjects (≥16 to 80 Years of Age) With Partial Seizures With or Without Secondary Generalization
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Nov 2023
Price :
$35
*
At a glance
- Drugs Brivaracetam (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors UCB Biopharma
- 05 Jul 2022 Status changed from active, no longer recruiting to completed.
- 27 Jun 2022 Planned End Date changed from 1 Jul 2022 to 29 Jul 2022.
- 27 Jun 2022 Planned primary completion date changed from 1 Jul 2022 to 29 Jul 2022.